Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection

Jesús Rufino, Carlos Baquero, Davide Frey, Christin A. Glorioso, Antonio Ortega, Nina Reščič, Julian Charles Roberts, Rosa E. Lillo, Raquel Menezes, Jaya Prakash Champati, Antonio Fernádez Anta
doi: https://doi.org/10.1101/2022.01.21.22269636
Jesús Rufino
2IMDEA Networks Institute, Spain
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Baquero
3U. Porto & INESC TEC, Portugal
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davide Frey
4Univ Rennes, IRISA, CNRS, Inria, 35042 Rennes, France
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christin A. Glorioso
5Academics for the Future of Science, Inc. & U. of California San Francisco, USA
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Ortega
6U. Southern California, USA
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Reščič
7Jožef Stefan Institute, Department of Intelligent Systems, Ljubljana, Slovenia
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julian Charles Roberts
8Gearu LTD, UK
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa E. Lillo
9U. Carlos III de Madrid, Spain
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raquel Menezes
10Centre of Mathematics of U. Minho, Portugal
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaya Prakash Champati
2IMDEA Networks Institute, Spain
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Fernádez Anta
2IMDEA Networks Institute, Spain
1CoronaSurveys Team, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: antonio.fernandez{at}imdea.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Data collected in the Global COVID-19 Trends and Impact Surveys (UMD Global CTIS), and data on variants sequencing from GISAID, are used to evaluate the impact of the Omicron variant (in South Africa and other countries) on the prevalence of COVID-19 among unvaccinated and vaccinated population, in general and discriminating by the number of doses. In South Africa, we observe that the prevalence of COVID-19 in December (with strong presence of Omicron) among the unvaccinated population is comparable to the prevalence during the previous wave (in August-September), in which Delta was the variant with the largest presence. However, among vaccinated, the prevalence of COVID-19 in December is much higher than in the previous wave. In fact, a significant reduction of the vaccine efficacy is observed from August-September to December. For instance, the efficacy drops from 0.81 to 0.30 for those vaccinated with 2 doses, and from 0.51 to 0.09 for those vaccinated with one dose. The study is then extended to other countries in which Omicron has been detected, comparing the situation in October (before Omicron) with that of December. While the reduction measured is smaller than in South Africa, we still found, for instance, an average drop in vaccine efficacy from 0.53 to 0.45 among those vaccinated with two doses. Moreover, we found a significant negative (Pearson) correlation of around −0.6 between the measured prevalence of Omicron and the vaccine efficacy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work is partially supported by grant CoronaSurveys-CM, funded by IMDEA Networks and Comunidad de Madrid, Spain, and individual donations to the CoronaSurveys Project https://coronasurveys.org.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Board of IMDEA Networks Institute gave ethical approval for this work on 2021/07/05. IMDEA Networks has signed Data Use Agreements with Facebook, Carnegie Mellon University (CMU) and the University of Maryland (UMD) to access their data, specifically UMD project 1587016-3 entitled C-SPEC: SymptomSurvey: COVID-19 and CMU project STUDY202000000162 entitled ILI Community-Surveillance Study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • * This work is partially supported by grant CoronaSurveys-CM, funded by IMDEA Networks and Comunidad de Madrid, Spain, and individual donations to the CoronaSurveys Project https://coronasurveys.org.

Data Availability

The data presented in this paper and some of the programs used to process it are openly accessible at https://github.com/GCGImdea/coronasurveys/tree/master/papers/omicron_efficacy_paper_medRxiv.

https://github.com/GCGImdea/coronasurveys/tree/master/papers/omicron_efficacy_paper_medRxiv

https://raw.githubusercontent.com/GCGImdea/coronasurveys/master/data/estimates-confirmed/PlotData/

https://raw.githubusercontent.com/GCGImdea/coronasurveys/master/data/common-data/unified-country-list.csv

https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/owid-covid-data.csv

https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/variants/covid-variants.csv

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 21, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection
Jesús Rufino, Carlos Baquero, Davide Frey, Christin A. Glorioso, Antonio Ortega, Nina Reščič, Julian Charles Roberts, Rosa E. Lillo, Raquel Menezes, Jaya Prakash Champati, Antonio Fernádez Anta
medRxiv 2022.01.21.22269636; doi: https://doi.org/10.1101/2022.01.21.22269636
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection
Jesús Rufino, Carlos Baquero, Davide Frey, Christin A. Glorioso, Antonio Ortega, Nina Reščič, Julian Charles Roberts, Rosa E. Lillo, Raquel Menezes, Jaya Prakash Champati, Antonio Fernádez Anta
medRxiv 2022.01.21.22269636; doi: https://doi.org/10.1101/2022.01.21.22269636

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3269)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)